

Summer/Fall 2020

accelerator

The Magazine of
the Multiple Myeloma
Research Foundation



UNLOCKING THE POWER OF PATIENT DATA

With the MMRF CureCloud[®],
patients drive progress.

Immune Atlas

Revealing our first results

Myeloma Investment Fund

Two new partnerships

MyCheckpoint Launches

A new platform trial

MMRF Events

We've gone virtual



A MESSAGE FROM PAUL GIUSTI

Dear MMRF Friends and Supporters,

This year has presented many unexpected challenges for all of us in the multiple myeloma community. Challenging times, however, can drive action, innovation and progress, while at the same time strengthening purpose, vision and resolve. The MMRF remains resolute in our mission—to find a cure for each and every multiple myeloma patient. Despite the pandemic, we've made remarkable progress in many areas this year.

A few highlights include:

The MMRF CureCloud® opens for patients:

We launched our biggest, boldest and most disruptive initiative ever—The MMRF CureCloud®. The CureCloud features the first free at-home genomic testing program for multiple myeloma and returns critical information about their disease back to each patient. With patients joining the CureCloud, we will aggregate data, accelerate research efforts and find better, smarter treatments for every myeloma patient.

Myeloma Investment Fund adds new investment:

The MMRF's Myeloma Investment Fund (MIF) announced an equity investment in Cullinan MICA, a promising biotech company advancing a novel immunotherapy approach to treat multiple myeloma. The MMRF research, science and bioinformatics teams worked closely with the company in optimizing their research plans. Cullinan MICA is the third MIF investment this year alone—engaging with the dynamic biotech industry to bring new myeloma therapies to patients.

MMRF announces new innovative immune platform trial:

In partnership with our MMRC (Multiple Myeloma Research Consortium), the MMRF is initiating MyCheckpoint,™ a first-of-its-kind platform trial examining the role of immune checkpoint inhibitors—engineered antibodies that block the ability of myeloma cells to turn off T-cell responses, thereby allowing a patient's immune system to recognize and kill myeloma cells. MyCheckpoint is designed to develop new treatment options for patients who are no longer responding to Darzalex.

Know that the MMRF has not slowed down, and we will continue to pursue our mission with a laser-like focus. Thank you for your interest in and dedication to the MMRF and to our shared fight against multiple myeloma.

Together, we are making amazing progress.


Paul Giusti
President and Chief Executive Officer

accelerator

The Magazine of the Multiple Myeloma Research Foundation | Summer/Fall 2020



MMRF Honored
for 18TH Year with
Highest Rating!



05 MYELOMA INVESTMENT FUND (MIF)

A new precision medicine initiative by the MMRF

04 IMMUNE ATLAS

- Revealing our first results

05 MYELOMA INVESTMENT FUND (MIF)

- Investing in Cullinan Mica & Abcuro

06 MMRF CURECLOUD®

08 MMRF CURECLOUD® LAUNCH EVENT

10 CLINICAL TRIAL HIGHLIGHT

- Learn about MyCheckpoint™

INTRODUCING SARCLISA

- FDA approves new treatment

11 MMRF MYELOMA MENTORS

12 MMRF ONLINE

- The launch of our new site
- MMRF Patient Summits and Webinars

14 DONOR SPOTLIGHT

- Kevin's Legacy
- Learn how to create your own legacy

MMRF LEADERSHIP

- Meet Mindy Flinn

16 MMRF EVENTS

- New virtual platform
- Join a virtual 5K Walk/Run this fall
- Your support is more important than ever

18 A NOTE FROM KATHY GIUSTI


- During a crisis, keep pushing forward
- Democratizing patient care
- Why it's time for non-profits to reevaluate

19 CALENDAR OF EVENTS



06 MMRF CURECLOUD®

Unlocking patient data to accelerate cures



16 MMRF EVENTS

Finding a way to connect...virtually

IMMUNE ATLAS REVEALS FIRST RESULTS

As precision medicine in the myeloma field continues to evolve, the ability to determine the best treatment for each and every patient will hinge not only on identifying genomic subtypes but also on defining each patient's immune subtype. The Immune Atlas Initiative is a first step in mapping each patient's immune system and identifying immune subtypes.

In the initiative's first phase, each of the five partner institutions received the same set of patient bone marrow samples from the MMRF tissue bank. These samples were collected as part of the MMRF CoMMpassSM Study and used to map the genomic landscape for myeloma as part of CoMMpass.

Researchers at each institution analyzed the samples using their own methods, with the new goal of analyzing different immune cell populations in patients with long remissions (slow progressors) versus patients with short remissions

(fast progressors). The researchers shared all their results with each other for comparison and aggregated analysis.

Going forward, MMRF will work with Immune Atlas partners to develop a common set of protocols and reagents for use in myeloma immune analysis.

This fall, the Immune Atlas partners will begin immune analysis of CoMMpass patient samples using high-dimensional single cell RNA sequencing (scRNAseq) and mass cytometry (CyTOF) assays to create an immune profile for each CoMMpass patient. These immune profiles will be combined with genomic and clinical profiles for each patient to provide a comprehensive picture of multiple myeloma and immunity for each patient's specific disease subtype.

Over time, we will add additional immune profiling technologies to the Immune Atlas protocol and expand our knowledge of immunity in multiple myeloma.

Immune Atlas Initiative Partners

Beth Israel Lahey Health
Beth Israel Deaconess Medical Center



“The MMRF plays a critical role in bringing together all the main actors in myeloma research—from the academic community to those in the pharmaceutical industry—to work together to determine how best to integrate and solve immune-based therapies in developing better treatments for our patients.”

David E. Avigan, MD, Beth Israel Deaconess Medical Center

Myeloma Investment Fund partners with Cullinan MICA and Abcuro



Capitalizing on the MMRF's scientific, bioinformatic and clinical expertise, the Myeloma Investment Fund (MIF) launched one year ago—a bold new venture philanthropy fund to attract oncology companies with promising clinical assets and innovative technologies.

Following the MIF's earlier investments in NexImmune and Tidal Therapeutics, the fund rapidly closed two new investments. Each advances novel immunology agents that aim to teach the immune system to recognize and destroy cancer cells.

The MIF recently partnered with San Diego, CA-based Cullinan MICA. Joining fellow investors Cullinan Oncology, Avalon Ventures, and Bregua Corporation in this \$26 million Series A financing round. Cullinan MICA focuses on antibody inhibitors targeted to specific protein disulfide isomerases that will 'unmask' tumor cells, activating patient immune systems so that they will seek out and eliminate the cancerous cells. Using data from the landmark MMRF CoMMpassSM Study, our team found evidence to support the potential for this novel approach. Now, thanks to this collaboration and the MIF's resulting investment, Cullinan MICA will include multiple myeloma patients in its Phase 1 clinical trial.

We've also partnered with Abcuro, an exciting biotechnology startup based in Newton, MA, that is focused on developing immune checkpoint inhibitors for autoimmune diseases and cancers that are modulated by cytotoxic T and NK cells. Abcuro is currently advancing two first-in-class preclinical programs; one of the programs focuses on multiple myeloma and was designed in close collaboration with the MMRF research, scientific and clinical teams. "We worked with the Abcuro team to develop a set of experiments to test the effectiveness of their anti-KLRG-1 antibody, a next-generation immune checkpoint inhibitor, against myeloma. Our investment will fund these experiments, with the option of a larger investment based on promising results," stated Peter Kosa, PhD, Myeloma Investment Fund Managing Director.

As a venture philanthropy fund, the MIF does not pay distributions to management or investors. All returns on our investments are directly reinvested back into research. Our pipeline of innovation will continue, improving outcomes as more patients gain access to effective, potentially breakthrough treatments and accelerating our efforts to find a cure.


For more information about the Myeloma Investment Fund go to MyelomaInvestmentFund.org.

"Our investment will fund experiments like those we developed with Abcuro to test the effectiveness of a next-generation immune checkpoint inhibitor against myeloma."

Peter Kosa, PhD
Myeloma Investment Fund Managing Director



CureCloud®



**UNLOCKING
THE POWER OF
PATIENT DATA**

CureCloud continues the MMRF's tradition of disrupting cancer research

For over 20 years, the Multiple Myeloma Research Foundation (MMRF) has been laser-focused on accelerating cures. Each of the MMRF's breakthrough initiatives—and by extension, our innovations—have built upon our previous successes with boldness and audacity.

From the first multi-center tissue bank to mapping the myeloma genome to launching the MMRF CoMMpassSM Study, we have come a long way and gained invaluable insights into multiple myeloma that have helped us advance better, more precise treatments.

Our landmark CoMMpass Study led to the identification of the largest genomics data set that distinguished subtypes, defined which patients might be higher risk, and identified new targets that we then took to MyDRUG, the first platform trial in myeloma.

In July, we launched our biggest, boldest and most disruptive initiative ever—the MMRF CureCloud[®]. Featuring the first free at-home genomic testing program for multiple myeloma and the most comprehensive data repository of its kind, CureCloud will become an invaluable resource to the scientists, doctors, and patients working to improve patient care and outcomes.

While CoMMpass has answered so many questions about the biology of myeloma,

CureCloud is the next step to uncover more answers to the questions we hear from patients every day:

- What is the best treatment for my subtype—from diagnosis through relapse?
- When is the right time for immunotherapy?
- I'm a Smoldering Multiple Myeloma patient; should I be treated?

We have been building CureCloud for over three years, investing millions of dollars and leveraging both the MMRF's expertise in establishing large data sets and building collaborations across the myeloma community. We believe that generating data is critical to understanding and curing myeloma, and we are committed to building out a data set that will lead to a cure for every patient.

This entire effort took visionary leadership and profound determination to advance better, more precise treatments. It is not an overstatement to say that no one else in the cancer community or even in the broader disease advocacy community could have pulled off such a major initiative. It takes real leadership—in science, in data, and in the clinic—to reach patients, and partner with the entire ecosystem to make a difference for myeloma patients everywhere.

Thanks to our ability to build trust, our ability to scale, our utter relentlessness, and most importantly, our leadership, every cancer, every disease will benefit from our work. We've built the models. We've done the heavy lifting. And we will share this model as broadly as we can.

As MMRF Founder Kathy Giusti has said, putting the power of knowledge into the hands of the patient is the greatest gift we could possibly give to every myeloma patient and every family facing a difficult diagnosis. CureCloud will give them that power.

“The CureCloud effort took visionary leadership and profound determination to advance better, more precise treatments.”

Anne Quinn Young, MPH
MMRF Chief Marketing & Development Officer

The MMRF CureCloud® revolutionizes research with at-home genomic testing

The MMRF CureCloud® is the first research study of its kind and includes an at-home genomic testing program, designed to inform smarter, more informed treatment options for every patient. By building a hub with vast amounts of genomic and clinical data, the MMRF CureCloud will give researchers, doctors and patients insights and information they can't get anywhere else.

CureCloud's unique characteristics could unlock answers to better treatment paths for myeloma patients. Participants will receive free tests and resources that enable more productive and informed conversations with multiple myeloma care teams.



Genomic test

Get a free state-of-the-art at-home genomic test, using the first-ever liquid biopsy for multiple myeloma.



Personal report

Receive a free report on the genetic variations in your multiple myeloma cells.



Coming soon: Smarter treatment options

You and your care team can identify more informed treatment paths based on other patient data.

Visit [MMRFCureCloud.org](https://www.MMRFCureCloud.org)
or call 1-888-841-MMRF (6673)

“The MMRF CureCloud® offers patients and doctors access to cutting-edge sequencing and personalized understanding at no cost. Information derived from this study will provide valuable insights benefiting the entire myeloma community while advancing treatment options for all patients.”

Steve Labkoff, MD, FACP, FACMI
MMRF Chief Data Officer

How Does the MMRF CureCloud® Work?



Online enrollment

Sign up on the MMRF CureCloud® website—visit [MMRFCureCloud.org](https://www.MMRFCureCloud.org).



Doctor approval

Your doctor approves your blood draw form for non-invasive genomic testing.



Free at-home blood draw

Get a free state-of-the-art genomic test at home.



Personalized insights


Receive a free personal report on the genetic variations in your multiple myeloma cells as well as information on available clinical trials based on your genomic makeup.



Discuss treatment options

Explore more precise treatment paths with your doctor.

CURECLOUD LAUNCHES WITH VIRTUAL EVENT



A star-studded, informative kickoff brings the MMRF CureCloud® to the myeloma community

On July 14TH, the MMRF officially launched CureCloud with an online event hosted by MMRF Chief Marketing and Development Officer Anne Quinn Young, MPH, and ESPN analyst Rodney Gilmore, who is also an MMRF Board Member and a myeloma patient.


“The MMRF is at it again, disrupting care for the better for patients everywhere,” said Gilmore. “CureCloud is a transformational innovation that shows how much more care patients can get today.”

The launch event featured appearances by MMRF supporters and patients, including Tom Brokaw, Dick Parsons, Mark Harrison and Mimi Kim. Also in attendance were our partners, including Dr. Craig Tendler, Janssen Pharmaceuticals; Dr. Irene Ghobrial, Dana Farber; ESPN’s SportsCenter co-host Sage Steele and Colonel Gary Steele, and MMRF Founder Kathy Giusti. MMRF Honorary Board Member CeeLo Green provided entertainment.

A special thanks to all our friends and supporters who made this launch possible, including Barbara and John Bowlin, Rebecca and Mark Dreyfus, Sabina and Harlan Stone, and representatives from the Horace W. Goldsmith Foundation, among many others whose generous commitments helped make the CureCloud possible.

MMRF LAUNCHES NEW MYCHECKPOINT PLATFORM TRIAL

The MMRF recently opened the first sites in the novel MyCheckpoint™ (NCT04150965) immune therapy platform trial, the first of its kind in multiple myeloma.



These agents do not attack the tumor directly; they are monoclonal antibodies that block “immune checkpoints”—molecules on the surface of cells that can turn off T-cell immune responses. When the checkpoint is blocked, T-cells are re-activated and able to destroy myeloma cells.

Through MyCheckpoint, myeloma patients who

have exhausted all other treatment options will be treated with a checkpoint inhibitor directed against either LAG-3 or TIGIT, combined with Pomalyst and dexamethasone.

MyCheckpoint will ultimately enroll 104 patients at 10 MMRC sites.

Questions? Please contact our Patient Navigator Center.

Monday–Friday (9AM–7PM ET)
1-888-841-MMRF(6673)




SARCLISA[®]
(isatuximab-irfc)

Injection for IV use | 500 mg/25 mL, 100 mg/5 mL

FDA approves Sarclisa for multiple myeloma

On March 3, the US Food and Drug Administration approved Sarclisa (isatuximab-irfc) for use in multiple myeloma. Sarclisa is an anti-CD38 monoclonal antibody that helps the body find and destroy myeloma cells.

The drug has been approved for intravenous use in combination with Pomalyst (pomalidomide) and dexamethasone in adult multiple myeloma patients who have received at least two prior therapies, including Revlimid (lenalidomide) and a One Cycle* proteasome inhibitor.

The MMRF and the Multiple Myeloma Research Consortium (MMRC) played a role in the early development of Sarclisa. The MMRC facilitated phase 1 and phase 2 clinical trials evaluating its use as a single agent and in combination with other myeloma therapies.



MEANINGFUL CONNECTIONS

With Myeloma Mentors, the MMRF connects patients to other patients like them

Our goal is the right care for every patient at the right time. And the right care involves more than treatments; support is critical to getting every patient what they need. To provide more patients and caregivers with needed support—and build a stronger community—the MMRF has launched the Myeloma Mentors program.

The Myeloma Mentors program connects patients with a Mentor like them—one who shares their diagnosis and characteristics. This is especially critical in myeloma care, given that myeloma is a heterogenous disease. Myeloma Mentors are trained patients and caregivers who share their experiences and journeys with multiple myeloma.

Through our phone-based program, any patient or caregiver can call and connect one-on-one with a trained mentor over a private line. To make this interaction as meaningful as possible, callers will be matched with mentors based on specific questions and shared characteristics. Mentors do not give medical advice; they are able to share important personal experiences with diagnosis, various treatments, and the experience of living with myeloma.

If you want to connect with someone who understands, contact the Patient Navigation Center and ask to be connected to a Myeloma Mentor.

888-841-MMRF (6673) or email us at PatientNavigator@TheMMRF.org

Our cure myeloma

The Multiple Myeloma Research Foundation drives discoveries for new treatments, groundbreaking clinical trials and data-driven initiatives in cancer research to find a cure for each and every patient with multiple myeloma.

FINDING THE ANSWERS YOU NEED

New patient-centric website design puts MMRF tools at patients' fingertips

We know patients and caregivers rely on us for myeloma education, connection and guidance. We want to make that as easy—and useful—as possible for you.

We're happy and proud to welcome you to the newly launched [TheMMRF.org](https://www.themmr.org)

Here are a few things you can expect from the new website:

- Find opportunities to learn more about multiple myeloma and how to treat it.
- Follow the MMRF's progress in advancing toward a cure and even ways to donate or get involved with fundraising.
- Keep up to date with all MMRF programming on the Events page.
- Reach resources for connection and support via the Patient Navigation Center.



Patient Summits

Our Patient Summit series has been transformed to a virtual format to continue reaching patients during the COVID-19 pandemic. We hosted Summits in March and August, reaching nearly 600 patients and caregivers, discussing the state of myeloma care including information on dealing with Coronavirus. Participants were able to take part in Q&A sessions with faculty.

MMRF Webinars

Our Patient Webinars have continued monthly, and we have hosted seven informative webinars with topics including the following:

- Learn your labs
- Supportive care
- Smoldering myeloma
- Managing myeloma during the COVID-19 pandemic
- Multiple myeloma highlights from the 2020 American Society of Clinical Oncology (ASCO) annual meeting
- The latest updates on CAR T-Cell therapies
- The latest updates on minimal residual disease

MMRF Expert Sessions—NEW!

We are excited to announce the first MMRF Expert Sessions. Crafted with patients and caregivers in mind, this 2-hour format was developed to provide patients and their families insights into clinical advancements and hot topics in myeloma, with a focus on immunotherapy and precision medicine. Our first virtual Expert Session was held in May and reached over 700 patients and caregivers.

COVID-19 Updates for Patients—NEW!

Drs. Hearn Jay Cho, Saad Z. Usmani, and Zainab Shahid led eight weekly 30-minute video webcasts to keep multiple myeloma patients and caregivers informed on the latest updates during the COVID-19 pandemic. The webcasts took place every Tuesday at 6PM EDT from June 2ND through July 21ST and featured national and international faculty. All eight webcasts are available for replay on our website.

Visit [TheMMRF.org/PatientED](https://www.mmrff.org/patiented)

To learn more about or view any of our past Patient Summits, Webinars, Expert Summits or COVID-19 webcasts—as well as to register for upcoming events.

Donor Spotlight:

LEGACY GIFT FROM KEVIN WELLS-KNECHT EXTENDS LIVES

The Multiple Myeloma Research Foundation (MMRF) is grateful for the support of those who choose to establish a legacy that will accelerate groundbreaking research and the discovery of new treatments for multiple myeloma patients. Kevin Wells-Knecht, a scientist and cyclist, made such a commitment.

Kevin passed away last year, but he made sure that the multiple myeloma community received the support critical to the development of better treatments. As Kevin's brother Mike said, "By including the MMRF in his estate, Kevin sought to advance research toward a cure and ensure that others diagnosed with his condition do indeed see hope."

Kevin was diagnosed with type 1 diabetes at age 13 and multiple sclerosis in his early 30s. During his treatment, routine blood tests revealed that he also had multiple myeloma.

Governed by a healthy lifestyle and long-distance cycling, Kevin sought to



use his passion for science to help find new treatments so that no one else had to share his struggle. Encouraged by his father, a chemical engineer, Kevin pursued and earned a doctorate in chemistry, studying the possible mechanisms in the development of diabetes complications. He went on to work in drug discovery in the fields of diabetes, oncology and virology. In his spare time, he volunteered with diabetic children struggling to cope with their disease.

Kevin's incredible generosity will help bring a cure to every patient and gives us all hope for a future without multiple myeloma.

Join the Legacy Society and Leave a Lasting Gift

Members of the Legacy Society have expressed their commitment to the Multiple Myeloma Research Foundation (MMRF) by naming us as the ultimate beneficiary of a planned gift, including a bequest in a will or living trust, as a beneficiary of a retirement plan or life insurance policy, or with a gift of personal property.

If you'd like to leave a lasting legacy through the MMRF, please contact Mindy Flinn, Vice President of Development at Flinnm@theMMRF.org or at 203-652-0462.

Introducing Mindy Flinn

Mindy Flinn joined the MMRF in May 2020 as the VP of Development. In her new role, she works with a talented team to raise philanthropic support for the organization. Mindy brings over 23 years of development experience with her to the MMRF, which includes her work at the Mayo Clinic, LIVESTRONG Foundation and the Yale School of Medicine.

In her free time, she enjoys skydiving and has climbed Mt. Kilimanjaro as a member of Survivor Summit.



EXPECT RESULTS.

Fundraising is needed now more than ever to accelerate critical research efforts and cures for every patient.

Join the myeloma community from around the world on the MMRF's new virtual events platform and help to advance our critical research efforts through fundraising. This new virtual events program brings us together to support our urgent mission — finding a cure for each and every patient diagnosed with multiple myeloma.

MMRF Events: Crucial to a Cure.

Make an impact today, register at [TheMMRF.org/Events](https://www.themmr.org/events)





MMRF EVENTS GO VIRTUAL



Myeloma will not stop, so neither can we

Finding a cure depends on everyone in the myeloma community—and we need your help to accelerate our mission now more than ever. Last year, the MMRF Events program reached over 30,000 people in the myeloma community and raised nearly \$10 million for a cure.

In 2020, our traditional Events portfolio has been transformed into an extraordinary virtual platform with endless and exciting ways to raise money for a cure. Until we can be together again in person, we encourage each of you to learn more and to register for the event (or events!) that inspire you.

- **MMRF Fall Awards—A Virtual Event:** The MMRF Fall Awards goes national! On Tuesday, October 13TH, 2020, at 6:30PM (CST), the MMRF will host a virtual event with MMRF Founder Kathy Giusti and cancer thriver & Good Morning America's co-anchor Robin Roberts.
- **MMRF 5K Walk/Runs:** Create a virtual team for one or all of our 13 events.
- **MMRF Move for Myeloma:** This NEW virtual challenge invites you to pick the distance you want to run, hike, bike, skip, stroll or move. Participate in your backyard, in your neighborhood, on your treadmill—anywhere!
- **MMRF Endurance Events:** Our endurance athletes are unstoppable! The 2020 MMRF Moving Mountains for Multiple Myeloma team will be lacing up their hiking boots in early 2021 with brand new hiking adventures for Fall 2021 to be announced soon. Save the date for The Journey Race Series as a virtual relay on October 3RD, allowing athletes everywhere to participate at their own distance. Our MMRF Road to Victories cycling program will be back stronger than ever in 2021. Stay tuned as the program expands to new distances for 2022.
- **MMRF Independent Events:** Take your everyday passions and utilize your talent to create unique events like a virtual yoga class, or live stream a musical concert.

Visit TheMMRF.org/Events to learn more and sign up today!

We will continue to raise money for research and build a community of patients, caregivers, pharmaceutical partners, doctors and donors. Innovation, results and urgency are at the core of all that we do, and that has not changed. Now, more than ever, we need to come together to find a cure.

We are grateful to the commitment of our event sponsors:

- | | | |
|----------------------------|---------------------------|-------------------|
| • AbbVie | • Dr. Elsey's | • Oncopeptides |
| • Adaptive Biotechnologies | • GlaxoSmithKline | • Sanofi Genzyme |
| • Bristol Myers Squibb | • Janssen Oncology | • Takeda Oncology |
| • CURE | • Karyopharm Therapeutics | |





A Note From Founder and Chief Mission Officer Kathy Giusti:

During a Crisis, Keep Pushing Forward

During times such as these, individuals and organizations are confronted with a choice. Do we hunker down, dig in our heels, and stick with the status quo? Or do we press forward, approaching a crisis as a unique opportunity to take bold and aggressive action?

Cancer patients know that in difficult situations, it is essential to be resilient and determined and to constantly move ahead. And in my career, I have found that challenging times often bring out the best in people and organizations. Out of crises can come incredible progress.

With this as a lens for viewing our current environment, I am proud that two strong teams I have had the honor of working with have forged ahead in recent months to launch innovative initiatives to support patients.

The MMRF launched CureCloud® to democratize patient care.

The MMRF is rising to the challenge. Our leadership team has worked diligently over the years to establish an ambitious, detailed and smart strategic plan.

Then the world changed overnight.

Harkening back to that strategic plan, with appropriate pivots, the team evaluated what could shift into this new virtual world—including launching the MMRF CureCloud®, deepening our Venture portfolio and planning clinical opportunities.

Why has MMRF CureCloud been our focus? To build a critical mass of data to help answer patients' questions and to make sequencing available to those who need it.

The HBS Kraft Accelerator launched an innovative playbook to democratize knowledge for cure-seeking organizations.

With so many disease-focused organizations struggling for funding, it is an essential time for non-profits to reevaluate their strategies, leadership and funding models.

After working with over 300 business leaders and non-profit disruptors, Harvard Business School's Kraft Accelerator is excited to launch an innovative new digital Playbook. This Playbook contains insights, knowledge and tools that cure-seeking organizations can use to impact all cancers and diseases. Organizations can leverage the Playbook to accelerate their own pursuit of cures.

These launches illustrate that even during challenging times, it is essential to keep your foot on the gas. Patients have no time to wait; every minute is precious as we search for cures.

2020 Fall & Winter Calendar of Events

MMRF TEAM FOR CURES: 5K WALK/RUN

September 13	Chicago 5K	Virtual
September 19	Boston 5K	Virtual
September 20	Twin Cities 5K	Virtual
September 27	Philadelphia 5K	Virtual
October 3	Tri-State 5K	Virtual
October 4	Washington, DC 5K	Virtual
October 10	Dallas 5K	Virtual
October 17	New York City 5K	Virtual
October 24	Charlotte 5K	Virtual
November 1	San Francisco 5K	Virtual
November 8	Atlanta 5K	Virtual
November 22	Los Angeles 5K	Virtual

MMRF ENDURANCE EVENT

October 3	The Journey Race Series	Virtual
-----------	-------------------------	---------

MMRF INDEPENDENT EVENT

October 29	Wine and Dine in the D	Virtual
------------	------------------------	---------

MMRF SIGNATURE EVENT

October 13	MMRF Fall Awards	Virtual
------------	------------------	---------

Events are subject to change; for more information visit: TheMMRF.org/Events.

Looking for guidance?

We're here to help. The professionals at our Patient Navigation Center can offer insights, counseling and support throughout your treatment journey.

Give us a call, Mon.-Fri., 9AM-7PM ET, **888-841-MMRF (6673)** or email us at PatientNavigator@TheMMRF.org

Sponsors:

We thank our sponsors for their support of *accelerator*, The Magazine of the Multiple Myeloma Research Foundation.

abbvie

Bristol Myers Squibb

Genentech

Karyopharm
Therapeutics

oncopeptides

Takeda | ONCOLOGY

cure®

CURE magazine helps patients, survivors and caregivers navigate the cancer experience and understand their diagnosis and treatment. For a free subscription, go to www.CureToday.com/Subscribe

accelerator

The Magazine of the Multiple Myeloma Research Foundation | Summer/Fall 2020

MULTIPLE MYELOMA RESEARCH FOUNDATION

383 Main Avenue, 5th Floor, Norwalk, CT 06851

Phone: 203-229-0464

Fax: 203-972-1259

Email: info@themmrf.org

Web: TheMMRF.org

THE MMRF ONLINE:



BOARD OF DIRECTORS

Mike Mortimer
Chairman

Lori Tauber Marcus
Vice Chairman

Kenneth Anderson, MD

Karen E. Andrews

Thomas Conheeny

Rodney Gilmore

Kathy Giusti

Paul Giusti

Dana LaForge

David L. Lucchino

Hugh Martin

Susan Marvin

Gerald McDougall

William S. McKiernan

David R. Parkinson, MD

Marie Pinizzotto, MD, MBA

Michael Reinert

Rodger Riney

Steven Shak, MD

Meryl Zausner

EXECUTIVE LEADERSHIP TEAM

Kathy Giusti, MBA
Founder and Chief Mission Officer MMRF and MMRC

Paul Giusti, MBA
President and Chief Executive Officer

Michael Andreini
Chief Operating Officer

Daniel Auclair, PhD
Chief Scientific Officer

Hearn Jay Cho, MD, PhD
Chief Medical Officer

Steven Labkoff, MD, FACP, FACMI
Chief Data Officer

Rob Miani
Chief Financial Officer

Anne Quinn Young, MPH
Chief Marketing and Development Officer

Karen Dietz, JD, MBA
General Counsel and Secretary

Mindy Flinn, MBA
Vice President, Development

Laura Gilman
Vice President, Events

Greg Rubenstein
Vice President, Marketing & Communications

Christopher Williams
Vice President, Business Development

HONORARY BOARD

Dusty Baker

James T. Brown

Bob Costas

Katie Couric

Cindy Crawford

Ann Curry

Clive J. Davis

CeeLo Green

Scott Hamilton

Mariska Hargitay

Lou Holtz

Bonnie Hunt

Senator Kay Bailey Hutchison

Dan Jansen

Hoda Kotb

Diana Krall

Sugar Ray Leonard

Tara Lipinski

Wynton Marsalis

Marlee Matlin

Eric McCormack

Deborah Norville

Sharon Osbourne

Carl Quintanilla

Al Roker

Sage Steele

Brian Williams

Pat Williams

Bob Woodruff

Lee Woodruff



The information herein is not intended to replace the services of trained health professionals (or to be a substitute for medical advice). You are advised to consult with your healthcare professional in regard to matters relating to your health and, in particular, regarding matters which may require diagnosis or medical attention.

Copyright ©2020 Multiple Myeloma Research Foundation



EXPECT MORE FROM A JOURNEY

**YOU NEVER
EXPECTED
TO BE ON.**

When it comes to the treatment of multiple myeloma, learn how you can Expect More at TheMMRF.org

